TRAW · NASDAQ
Traws Pharma (TRAW) Stock Price & Fundamentals
Traws Pharma (TRAW) closed at $485.00 on Oct 9, 2026, down 0.98% from the previous close of $489.81.
Share price, past year
1Y −6.89%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $485.00 |
| Sep 30, 2026 | $501.11 |
| Aug 31, 2026 | $532.75 |
| Jul 31, 2026 | $534.05 |
| Jun 30, 2026 | $497.13 |
| May 29, 2026 | $525.61 |
| Apr 30, 2026 | $514.66 |
| Mar 31, 2026 | $519.54 |
| Feb 27, 2026 | $489.18 |
| Jan 30, 2026 | $492.90 |
| Dec 31, 2025 | $492.79 |
| Nov 28, 2025 | $512.94 |
| Oct 31, 2025 | $492.31 |
Key statistics
- Market cap
- $7.40B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.85
- Revenue (TTM)
- —
- Net income (TTM)
- −$21.57M
- Shares outstanding
- 15.3M
- Dividend yield
- —
- 52-week range
- $476.37 – $540.84
Traws Pharma's market cap is $7.40B, based on a share price of $485.00 and 15.3M shares outstanding as of Jun 30, 2026.
Financials
Traws Pharma reported revenue of $2.79M for fiscal 2024, up 1,134.51% from fiscal 2023.
Traws Pharma earned net income of $9.17M in fiscal 2024, a net margin of 328.7%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2024ended Dec 31, 2025 | $2.79M | +1,134.5% | $9.17M | 328.7% | $0.82 | — |
| FY2023ended Dec 31, 2024 | $226.00K | 0.0% | −$166.52M | −73,682.7% | −$35.21 | — |
| FY2022ended Dec 31, 2023 | $226.00K | 0.0% | −$18.95M | −8,384.1% | −$22.57 | −$17.95M |
| FY2021ended Dec 31, 2022 | $226.00K | 0.0% | −$18.96M | −8,391.2% | −$22.75 | — |
| FY2020ended Dec 31, 2021 | $226.00K | −2.2% | −$16.16M | −7,151.8% | −$24.00 | — |
| FY2019ended Dec 31, 2020 | $231.00K | −89.4% | −$25.16M | −10,890.5% | −$54.25 | −$23.09M |
| FY2018ended Dec 31, 2019 | $2.18M | +77.8% | −$21.50M | −985.0% | −$37.25 | −$20.89M |
| FY2017ended Dec 31, 2018 | $1.23M | +56.0% | −$20.57M | −1,675.3% | −$124.75 | — |
| FY2016ended Dec 31, 2017 | $787.00K | −85.8% | −$24.09M | −3,061.3% | −$1,003.75 | — |
| FY2015ended Dec 31, 2016 | $5.55M | — | −$19.67M | −354.6% | −$111.00 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2024ended Jun 30, 2025 | $2.73M | −$915.00K | −$0.11 |
| Q1 FY2024ended Mar 31, 2025 | $57.00K | $21.49M | $2.09 |
| Q4 FY2023ended Dec 31, 2024 | $56.00K | −$29.92M | −$7.28 |
| Q3 FY2023ended Sep 30, 2024 | $57.00K | −$8.48M | −$1.49 |
| Q2 FY2023ended Jun 30, 2024 | $57.00K | — | — |
| Q1 FY2023ended Mar 31, 2024 | $56.00K | — | — |
| Q4 FY2022ended Dec 31, 2023 | $56.00K | — | — |
| Q3 FY2022ended Sep 30, 2023 | $57.00K | — | — |
Company profile
- Name
- Traws Pharma, Inc.
- Ticker
- TRAW
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 12 Penns Trail, Newtown, PA 18940
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001130598
Recent SEC filings
- Aug 14, 2026
- Aug 14, 2026
- Jul 31, 2026
- Jul 10, 2026
- Jul 9, 2026
- Jun 22, 2026
- Jun 12, 2026
- May 27, 2026
Frequently asked questions
What is Traws Pharma's stock price?
Traws Pharma (TRAW) closed at $485.00 on Oct 9, 2026, down 0.98% from the previous close of $489.81.
What is Traws Pharma's market cap?
Traws Pharma's market cap is $7.40B, based on a share price of $485.00 and 15.3M shares outstanding as of Jun 30, 2026.
How much revenue does Traws Pharma make?
Traws Pharma reported revenue of $2.79M for fiscal 2024, up 1,134.51% from fiscal 2023.
Does Traws Pharma pay a dividend?
Traws Pharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Traws Pharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures